Combined PET/CT Imaging in Oncology Impact on Patient Management
- 1 December 2000
- journal article
- Published by Elsevier in Clinical Positron Imaging
- Vol. 3 (6), 223-230
- https://doi.org/10.1016/s1095-0397(01)00055-3
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Staging Non-Small Cell Lung Cancer with Whole-Body PETRadiology, 1999
- Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign VariantsRadioGraphics, 1999
- FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases?European Journal of Nuclear Medicine and Molecular Imaging, 1998
- Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s diseaseAnnals of Oncology, 1998
- Prospective comparison of 18 F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma.Journal of Clinical Oncology, 1998
- Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.Radiology, 1998
- FDG uptake, tumour characteristics and response to therapyNuclear Medicine Communications, 1998
- Noninvasive determination of local cerebral metabolic rate of glucose in manAmerican Journal of Physiology-Endocrinology and Metabolism, 1980
- Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of methodAnnals of Neurology, 1979